Alflutinib
$600.00
CAS No.: 1869057-83-9
Catalog No.: 194452
Purity: 95%
MF: C28H31F3N8O2
MW: 568.604
Storage: 2-8 degree Celsius
SMILES: CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C
Catalog No.: 194452
Purity: 95%
MF: C28H31F3N8O2
MW: 568.604
Storage: 2-8 degree Celsius
SMILES: CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C
Alflutinib; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide; CAS No.: 1869057-83-9;Alflutinib. PROPERTIES: Alflutinib is a white to off-white crystalline powder with a molecular formula of C33H32F6N4O3 and a molecular weight of 654.63 g/mol. It exhibits moderate lipophilicity with limited aqueous solubility. Proper storage requires keeping it at -20 C in a sealed amber vial protected from light. When handling, standard laboratory protective measures are recommended due to its potential to cause respiratory irritation if aerosolized. APPLICATIONS: Alflutinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. In oncology, it's used for treating non-small cell lung cancer (NSCLC) patients with EGFR mutations, demonstrating efficacy in both first-line and pretreated settings (source: Journal of Thoracic Oncology). Preclinical studies highlight its ability to overcome resistance to first-generation EGFR inhibitors through improved binding kinetics. Alflutinib also serves as a research tool for studying EGFR mutation landscapes and developing companion diagnostic strategies (source: Clinical Cancer Research).
Reviews
Write Your Own Review